UK MHRA Sets Path for Puberty Blocker Trial to Continue

UK Regulators Clear Puberty Blocker Trial to Resume with Safeguards

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have approved the continuation of the controversial Phase III PATHWAYS trial, investigating puberty blockers for children and young people with gender incongruence. The trial, run by King’s College London, was paused in February 2026 due to well-being concerns. Following a scientific dialogue, a modified protocol with strengthened safeguards, including minimum age requirements (11 for birth-registered females, 12 for birth-registered males) and clearer discontinuation measures, has been agreed upon. The study aims to provide robust evidence on the benefits and risks of gonadotropin-releasing hormone analogues like leuprolide acetate and triptorelin, though its commencement is subject to an ongoing judicial review.

• The MHRA and HRA have concluded their review of the PATHWAYS trial, which was paused in February 2026 due to participant well-being concerns. A modified protocol, meeting regulatory and ethical standards, has been approved, allowing the investigator-led Phase III study to proceed. This decision follows extensive and open engagement between the PATHWAYS research team and the MHRA to resolve questions raised.
• The updated protocol introduces several key safeguards, including minimum age requirements for entry set at 11 for birth-registered females and 12 for birth-registered males. It also specifies clearer discontinuation measures related to safety for bone health, cognition, and vaginal bleeding, alongside more detailed information on fertility preservation for participants.
• The PATHWAYS trial, investigating gonadotropin-releasing hormone analogues (GnRHa) such as leuprolide acetate and triptorelin, aims to build an evidence base on the effects of puberty suppression on quality of life, mental health, physical development, cognitive function, and gender-related distress. Recruitment is slated for August 1, 2026, pending the resolution of an ongoing judicial review challenging the regulators' decisions.

MHRA Clears PATHWAYS Trial with Strengthened Safety Protocols

Published literature demonstrates broadly acceptable safety and tolerability profiles for both leuprolide acetate and triptorelin across multiple indications, with adverse events largely consistent with their mechanism of GnRH agonism-induced sex hormone suppression. Head-to-head comparative data indicate no statistically significant difference in tolerability between the two agents, supporting their interchangeability in relevant therapeutic contexts.

• Prostate cancer (leuprolide acetate): The 7.5 mg intramuscular depot formulation administered every four weeks demonstrated a consistent safety profile in stage D2 prostate cancer, with no testosterone escape events (defined as two consecutive values >50 ng/dL) observed during 24 weeks following attainment of castrate levels. In the EMBARK trial, safety profiles for enzalutamide ± leuprolide versus leuprolide alone were comparable in patients with high-risk biochemical recurrence. A notable case report documented diffuse maculopapular dermatitis in an 80-year-old male following the fifth monthly injection, which progressed to a generalised rash; the condition resolved completely following a three-week course of prednisone without long-term sequelae.

• Breast cancer (leuprolide acetate and triptorelin): In premenopausal patients, monthly and 3-month leuprolide acetate depot formulations demonstrated equivalent tolerability, with musculoskeletal pain, hot flashes, fatigue, and insomnia as the most common treatment-related adverse events; one-year overall survival was 100% and 99% in the monthly and 3-monthly arms, respectively. For triptorelin combined with letrozole, 15.4% of patients experienced suboptimal ovarian function suppression after cycle 1, and the addition of triptorelin to tamoxifen or exemestane was associated with increased endocrine-deprivation symptoms, though no detrimental oncological outcomes were observed.

• Central precocious puberty (CPP) — comparative data: In a study of 110 girls with CPP, 41.8% of patients overall reported mild menopausal-like symptoms, with no statistically significant difference in tolerability between triptorelin and leuprolide (p = 0.558). Symptom profiles differed modestly: headache was more frequently reported with triptorelin (27.4% vs. 16.7%), while nausea (10.4% vs. 1.6%) and increased appetite (18.8% vs. 12.9%) were more common with leuprolide. Onset of GnRH agonist-related side effects decreased significantly with higher initial bone age (p = 0.038).

• Systemic lupus erythematosus (triptorelin): In adolescent females with childhood-onset SLE, high-dose triptorelin (120 µg/kg body weight) was well tolerated, with adverse event rates of 189 per 100 patient-months versus 362 for placebo, and serious adverse event rates of 2.1 versus 8.5 per 100 patient-months. Treatment at this weight-adjusted dose achieved sustained complete ovarian suppression in 90% of patients.

• Endometriosis — head-to-head data: In a study of 54 patients with pelvic endometriosis, the severity of menopausal symptoms and changes in lipid and liver function parameters were comparable between triptorelin and leuprorelin acetate, with both agents demonstrating equivalent potency in down-regulating pituitary-ovarian function. A separate endometrioma study noted that after nine weeks, anxiety, depression, vaginal dryness, headache, and acne rates were significantly lower in the leuprolide group compared to triptorelin.

• Bone marrow transplantation (leuprolide acetate): In premenopausal women undergoing BMT, leuprolide 1 mg daily IV administered for a median of 50 days was well tolerated, with no adverse effects directly attributable to the drug; it successfully prevented menstruation in 73% of patients.

• Melanoma (triptorelin): In male patients receiving triptorelin in combination with nivolumab and bicalutamide, the regimen was well tolerated overall, with no grade 4 or 5 adverse events recorded; five grade 3 adverse events were reported across four patients.

Unpacking the Modified PATHWAYS Trial's Inclusion Criteria

Pivotal trial design for gender incongruence has evolved considerably, though the overall evidence base remains limited. Across available studies, inclusion criteria vary by population focus, diagnostic framework, and therapeutic objective — reflecting both the heterogeneity of the field and the absence of a universally adopted trial standard.

• Diagnostic eligibility: The 2021 Japanese cohort study required patients to carry a formal diagnosis of gender identity disorder per ICD-10 classification, established across three institutions, prior to initiation of gender-affirming hormone therapy.

• Age thresholds: The 2020 Cochrane systematic review set a minimum age of 16 years for eligible transgender women transitioning from male to female. In the 2021 Japanese study, the median age at hormone therapy commencement was 24 years for transgender men and 28 years for transgender women.

• Sample composition: The 2021 Japanese study enrolled 336 transgender men receiving androgen therapy and 48 transgender women receiving estrogen therapy, illustrating the skewed representation common across early-phase evidence.

• Intervention eligibility: The 2020 Cochrane review restricted eligible studies to those investigating antiandrogen and estradiol hormone therapies — alone or in combination — compared against an active intervention or placebo, with the sole qualifying trial being an ongoing RCT in Thailand comparing estradiol valerate plus cyproterone against estradiol valerate plus spironolactone.

• Expanded population inclusion (PURPOSE 2, 2022): This Phase 3 lenacapavir PrEP trial broadened its eligible population to include cisgender MSM, transgender women, transgender men, gender nonbinary individuals, and adolescents — with mandated diversity recruitment targets of 50% Black MSM and 20% Hispanic/Latinx MSM at US sites, and 20% transgender women globally.

• Evidence gap: The 2020 Cochrane review identified no completed studies meeting its inclusion criteria, underscoring the absence of robust, completed RCT-level evidence on hormonal interventions for transgender women at the time of publication.

Addressing Unmet Needs in Puberty Blockers for Gender Incongruence

The clinical landscape for gender incongruence has expanded significantly, revealing a diverse set of unmet needs spanning reproductive health, mental health, and socioeconomic support. Emerging evidence highlights both distinct patient subpopulations requiring tailored interventions and systemic gaps in care infrastructure that limit access to gender-affirming services.

• Fertility preservation (FP) remains critically underutilized among transgender and gender-diverse (TGD) individuals, despite a prevalent desire to have children. The medical community lacks the understanding and infrastructure to serve the reproductive needs of transgender and non-binary people, and the unique biology and clinical care of TGD individuals have challenged the direct translation of FP options available to cisgender individuals — necessitating population-specific protocols and barrier reduction strategies.

• Mental health burden is high and care needs are largely unmet among transgender populations with psychiatric comorbidities. In a 2024 Indian study of 128 transgender women assigned male at birth, 72% met criteria for a DSM-5-TR mental disorder — most commonly major depressive disorder (40%) — and the mean number of identified needs on the CANSAS scale was 6.1, of which only 8.5% were met. The most frequently reported unmet needs included money (79.3%), welfare benefits (69.5%), psychological distress (44.5%), basic education (40.1%), intimate relationships (37%), accommodation (34%), transportation (32%), and information on condition and treatment (29.3%).

• Three clinically distinct pathways — childhood-onset, autogynephilic, and rapid-onset gender dysphoria — have been identified as requiring differentiated treatment approaches, with adolescent-onset dysphoria among natal females emerging as a previously unrecognized and now increasingly prevalent subtype.

• Understudied and emerging clinical populations include individuals with disorders of sexual development (DSD) such as 5-alpha reductase deficiency, congenital adrenal hyperplasia (CAH), and Turner syndrome (TS). Testosterone-based masculinizing therapy remains poorly studied in TS patients, with only one prior published adult case report before 2025; psychosocial support and multidisciplinary care are recognized as essential but inconsistently implemented in DSD cohorts.

• Adolescents with co-occurring functional tic-like behaviors (FTLBs) and gender dysphoria represent an underrecognized population requiring integrated psychiatric management. Comprehensive treatment — including psychotherapy (100% of patients) and pharmacologic intervention (78%), most commonly SSRIs and alpha-2 agonists — was associated with complete or near-complete resolution of FTLBs at 12-month follow-up, underscoring the importance of early recognition and multidisciplinary care.

PATHWAYS Trial: Navigating Evidence, Ethics, and Regulation

The decision by the UK's MHRA and HRA to approve the continuation of the Phase III PATHWAYS trial for puberty blockers marks a pivotal moment for the development and evaluation of treatments for gender incongruence. This move underscores a clear regulatory intent to gather robust clinical evidence for gonadotropin-releasing hormone analogues (GnRHa) in a therapeutic area that has been characterized by significant public and scientific debate. The complexity of pubertal development, a process intricately regulated by gonadotropin-releasing hormone, necessitates a deep understanding of how these interventions impact young people. While GnRHa are utilized in other gynecological contexts, the specific long-term outcomes in gender incongruence remain largely uncharacterized, highlighting a critical evidence gap that this trial aims to address.

The modified trial protocol, which includes enhanced safeguards such as minimum age requirements and clearer discontinuation criteria, reflects an evolving standard for ethical research in vulnerable populations. This approach sets a precedent for how pharmaceutical companies might design future studies in sensitive pediatric indications, emphasizing patient well-being and comprehensive risk assessment. However, the journey is not without its challenges. Concerns persist regarding the potential for expectancy and nocebo effects, particularly given the trial's waitlist control design and the timing of intervention for some participants. Furthermore, the literature suggests that even with modifications, there may still be safeguarding gaps, particularly for late pubertal female participants, which could expose them to foreseeable harms. The need for long-term data on hormonal therapies is well-documented, and this trial will be under intense scrutiny to provide definitive answers on both the benefits and risks of GnRHa in this population. Ultimately, the PATHWAYS trial's progress will not only shape the future of gender-affirming care but also influence the broader landscape of pharmaceutical development in areas where scientific rigor must navigate complex ethical, social, and legal considerations.